WHAT Oncology Results have been announced from a Phase II study of Q-122, a new non-hormonal oral therapy for the treatment of vasomotor symptoms (known as hot flashes and night sweats) in women undergoing endocrine therapy for breast cancer. Posted in scalpel.
Over 75% of breast cancers are hormone sensitive and endocrine therapy is the standard treatment option according to the Australian Breast Cancer Network. Endocrine therapy is recommended for 5 to 10 years after cancer treatment for women with hormone-sensitive breast cancer, to prevent disease recurrence. However, approximately 70% of women undergoing endocrine therapy experience vasomotor symptoms contributing to more than a third of women discontinuing this important treatment prematurely.
A phase II study was a multicenter, randomized, double-blind, placebo-controlled study that included 131 women, aged 18 to 70 years, who were taking a stable dose of tamoxifen or an aromatase inhibitor after breast cancer at least 50 self-reported moderate cases. to severe vasomotor symptoms per week.
Treatment with Q-122 significantly reduced the frequency and severity of moderate to severe vasomotor symptoms, with an associated improvement in quality of life, compared with placebo. Q-122 was well tolerated with no serious adverse effects.
These findings demonstrate Q-122’s promise as a novel, differentiated, nonhormonal treatment for vasomotor symptoms in women with breast cancer on endocrine therapy and the potential for its use in postmenopausal women with similar symptoms, according to QUE Oncology.
In addition to the reduction in hot flashes and sweats, women who received Q-122 in the study reported a significantly lower likelihood of hot flashes and sweats interfering with sleep and social and recreational activities compared to placebo. symptoms, it has potential. Significant in reducing endocrine therapy disruption, allowing continued protection against breast cancer recurrence. said Professor Susan Davis, principal investigator and lead author, director of Monash University Women’s Health Research Programme.
Results from the QUE Oncology Phase II study support larger, longer studies of Q-122, with the potential to extend its use to postmenopausal women who need an alternative to estrogen therapy for vasomotor symptoms.
